DORMANT studio
localhost:3000

Opportunity radar

4,186,134 patents indexed · 165,974,948 citations · issued 2005-01-04 → 2026-05-05

Showing50 of 77,862
Free-text
CPC starts with (comma sep)
Min fwd citations
Clear
Patent #TitleAssetsIssuedExpiresFwd citesScore
12606779Active agent-containing articles🖼🧊📄§2026-04-212043-08-28031
12605710Flow channel structure for removing foreign substance, method for removing foreign substance, and method for manufacturing lipid particles🖼🧊📄§2026-04-212043-03-13031
12605441Immunogenic trimers🖼🧊📄§2026-04-212044-06-04031
12605452Compounds that degrade kinases and uses thereof🖼🧊📄§2026-04-212040-06-03031
12606875Fish Totivirus🖼🧊📄§2026-04-212040-02-04031
12606523Deuterated organic compounds and uses thereof🖼🧊📄§2026-04-212044-07-03031
12605331Composition comprising iris-derived exosome as active ingredient🖼🧊📄§2026-04-212043-12-27031
12605334Method of enhancing the efficacy and stability of ingredients in suspensions🖼🧊📄§2026-04-212043-12-04031
12605402Therapeutic uses of oxidizing hypotonic acid solutions🖼🧊📄§2026-04-212040-07-02031
12606709Method for increasing specific surface area of titanium phosphate plate-shaped particles, and powder containing plate-shaped particles derived from titanium phosphate🖼🧊📄§2026-04-212040-05-15031
12605239Enhancement of hydration and improvement in gut health through cloacal delivery of products🖼🧊📄§2026-04-212041-07-29031
12605365Losartan liquid formulations and methods of use🖼🧊📄§2026-04-212042-12-05031
12605366Telmisartan for the treatment of hypertension in dogs🖼🧊📄§2026-04-212040-04-30031
12605446PSMA-targeted immunotherapies for cancers🖼🧊📄§2026-04-212041-08-20031
12605367Methods of treatment and/or prevention of disorders and symptoms related to BKCa and/or SK channelophathies🖼🧊📄§2026-04-212040-09-15031
12605414Discovery of novel Akkermansia muciniphila AK32 and application thereof for improving intestinal function🖼🧊📄§2026-04-212041-05-07031
12606598Chimeric klebicins🖼🧊📄§2026-04-212042-07-08031
12605332Transdermal delivery formulations🖼🧊📄§2026-04-212042-10-31031
12606796Delivery of oncolytic viruses using dendritic cells🖼🧊📄§2026-04-212040-05-07031
12605343Method for producing microbubble-containing electrolyte solution and method for producing microbubble-containing solvent used for preparing microbubble-containing electrolyte solution🖼🧊📄§2026-04-212040-08-24031
12605411Phospholipid compositions for delivery of therapeutic compounds🖼🧊📄§2026-04-212044-06-05031
12605415Compositions and methods🖼🧊📄§2026-04-212043-07-11031
12605412Microbial compositions for improving the efficacy of anticancer treatments based on immune checkpoint inhibitors and/or tyrosine kinase inhibitors and markers of responsiveness to such treatments🖼🧊📄§2026-04-212040-09-29031
12605355HA-paclitaxel conjugate for treatment of mesothelioma🖼🧊📄§2026-04-212041-04-07031
12606528Methods and materials for inhibiting NF-kB activity🖼🧊📄§2026-04-212040-11-20031
12605448Porous self-healing polymer matrix for encapsulation of active macromolecules and methods🖼🧊📄§2026-04-212040-07-20031
12605449Drug-clay mineral complex containing phospholipid and oral administration composition including same🖼🧊📄§2026-04-212041-07-01031
12605472Radiolabeling of anti-CD45 immunoglobulin and methods of use thereof🖼🧊📄§2026-04-212040-09-17031
12605471Cromolyn derivatives and related methods of imaging and treatment🖼🧊📄§2026-04-212043-06-02031
12605470Nanodroplet with layer-by-layer assembly🖼🧊📄§2026-04-212040-11-20031
12605473Methods for making radiolabeled anti-MET binding proteins🖼🧊📄§2026-04-212043-12-29031
12605465AAV-NAGLU vectors for treatment of mucopolysaccharidosis IIIB🖼🧊📄§2026-04-212041-03-22031
12605464Cyclohexane lipidoids for nucleic acid transfection and use thereof🖼🧊📄§2026-04-212042-07-15031
12605468Oxazine-based fluorophore compounds for nerve-specific imaging🖼🧊📄§2026-04-212041-01-22031
12605461Hydrogel compositions and uses thereof🖼🧊📄§2026-04-212040-07-03031
12605463Tolerogenic artificial antigen-presenting cells🖼🧊📄§2026-04-212040-06-12031
12605455CAR peptide for improved coronavirus survival🖼🧊📄§2026-04-212041-03-19031
12605451Targeted plasma protein degradation🖼🧊📄§2026-04-212041-02-04031
12605456Composition and method for HIP1-targeting inhibitor compounds🖼🧊📄§2026-04-212042-05-28031
12605436Chikungunya vaccine formulations🖼🧊📄§2026-04-212040-08-10031
12605442Production of vaccines comprising inactivated SARS-CoV-2 viral particles🖼🧊📄§2026-04-212041-03-05031
12605439Universal influenza vaccine compositions🖼🧊📄§2026-04-212041-12-28031
12605437Single shot Chikungunya virus vaccine🖼🧊📄§2026-04-212040-08-10031
12605429Proteins having pneumococcal capsule degrading activity and methods of use🖼🧊📄§2026-04-212043-05-19031
12605457Modified EGFR antibody with reduced affinity, drug conjugate, and use thereof🖼🧊📄§2026-04-212041-11-19031
12605433Antibody specifically binding to PTK7 and use thereof🖼🧊📄§2026-04-212041-07-16031
12605311Hydrogel structure🖼🧊📄§2026-04-212041-02-05031
12605310Non-aqueous dispersion, preparation method therefor, and cosmetic composition comprising same🖼🧊📄§2026-04-212039-10-08031
12605308Topical skin care formulations comprising plant extracts🖼🧊📄§2026-04-212043-10-18031
12605309Pressed powder product and method for preparing the same🖼🧊📄§2026-04-212043-05-25031